• Policy
• Why many choline alfoscerates accepted price cuts
• by Lee, Tak-Sun Sep 5, 2023 05:39am

• Policy
• New GLP-1 RA stops reimb discussions in KOR
• by Lee, Tak-Sun Sep 4, 2023 05:04am

• Policy
• Kanoa, the upper limit price was reduced further by PVA
• by Lee, Tak-Sun Sep 1, 2023 05:44am

• Policy
• MOHW ‘is discussing expanding non-face-to-face treatment’
• by Lee, Jeong-Hwan Sep 1, 2023 05:44am

• Policy
• The 1st results of the pharmaceutical benefit re-evaluation
• by Lee, Tak-Sun Sep 1, 2023 05:43am

• Policy
• Cold medicine bills increased by 90% due to the coronavirus
• by Lee, Tak-Sun Aug 31, 2023 05:25am

• Policy
• NHIS may cover high-priced new drugs with refund-type RSA
• by Lee, Tak-Sun Aug 31, 2023 05:25am

• Policy
• Opdivo reimb as first-line therapy in gastric cancer in KOR
• by Lee, Tak-Sun Aug 29, 2023 05:28am

• Policy
• Hyundai Pharm's Hypejil 3mg
• by Lee, Tak-Sun Aug 29, 2023 05:28am

• Policy
• MOHW-Roche have difficulty discussing resupply of Madopar
• by Lee, Jeong-Hwan Aug 28, 2023 05:21am